Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022

被引:22
作者
de Gier, Brechje [1 ]
van Asten, Liselotte [1 ]
Boere, Tjarda M. [1 ]
van Roon, Annika [1 ]
van Roekel, Caren [1 ]
Pijpers, Joyce [1 ]
van Werkhoven, C. H. Henri [1 ,2 ]
van den Ende, Caroline [1 ]
Hahne, Susan J. M. [1 ]
de Melker, Hester E. [1 ]
Knol, Mirjam J. [1 ]
van den Hof, Susan [1 ]
机构
[1] POB 1, NL-3720 BA Bilthoven, Netherlands
[2] Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands
关键词
COVID-19; Vaccine effectiveness; Mortality; SARS-CoV-2; UNITED-STATES; INFECTIONS; DEATHS; IMPACT;
D O I
10.1016/j.vaccine.2023.06.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: We aimed to estimate vaccine effectiveness (VE) against COVID-19 mortality, and to explore whether an increased risk of non-COVID-19 mortality exists in the weeks following a COVID-19 vaccine dose.Methods: National registries of causes of death, COVID-19 vaccination, specialized health care and long-term care reimbursements were linked by a unique person identifier using data from 1 January 2021 to 31 January 2022. We used Cox regression with calendar time as underlying time scale to, firstly, estimate VE against COVID-19 mortality after primary and first booster vaccination, per month since vaccination and, secondly, estimate risk of non-COVID-19 mortality in the 5 or 8 weeks following a first, second or first booster dose, adjusting for birth year, sex, medical risk group and country of origin. Results: VE against COVID-19 mortality was > 90 % for all age groups two months after completion of the primary series. VE gradually decreased thereafter, to around 80 % at 7-8 months post-primary series for most groups, and around 60 % for elderly receiving a high level of long-term care and for people aged 90+ years. Following a first booster dose, the VE increased to > 85 % in all groups. The risk of non-COVID-19 mortality was lower or similar in the 5 or 8 weeks following a first dose compared to no vaccination, as well as following a second dose compared to one dose and a booster compared to two doses, for all age and long-term care groups.Conclusion: At the population level, COVID-19 vaccination greatly reduced the risk of COVID-19 mortality and no increased risk of death from other causes was observed. (c) 2023 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4488 / 4496
页数:9
相关论文
共 28 条
[1]   Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines [J].
Andrews, Nick ;
Tessier, Elise ;
Stowe, Julia ;
Gower, Charlotte ;
Kirsebom, Freja ;
Simmons, Ruth ;
Gallagher, Eileen ;
Thelwall, Simon ;
Groves, Natalie ;
Dabrera, Gavin ;
Myers, Richard ;
Campbell, Colin N. J. ;
Amirthalingam, Gayatri ;
Edmunds, Matt ;
Zambon, Maria ;
Brown, Kevin ;
Hopkins, Susan ;
Chand, Meera ;
Ladhani, Shamez N. ;
Ramsay, Mary ;
Bernal, Jamie Lopez .
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04) :340-350
[2]   Risk of venous thrombotic events and thrombocytopenia in sequential time periods after ChAdOx1 and BNT162b2 COVID-19 vaccines: A national cohort study in England [J].
Andrews, Nick J. ;
Stowe, Julia ;
Ramsay, Mary Eb ;
Miller, Elizabeth .
LANCET REGIONAL HEALTH-EUROPE, 2022, 13
[3]  
European Medicines Agency, 2022, US
[4]   Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016-2018 [J].
Geurten, Rose J. ;
Struijs, Jeroen N. ;
Elissen, Arianne M. J. ;
Bilo, Henk J. G. ;
van Tilburg, Chantal ;
Ruwaard, Dirk .
PHARMACOECONOMICS-OPEN, 2022, 6 (02) :219-229
[5]  
government, Proof of vaccination: requirements and validity: Government of the Netherlands
[6]   Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data [J].
Haas, Eric J. ;
Angulo, Frederick J. ;
McLaughlin, John M. ;
Anis, Emilia ;
Singer, Shepherd R. ;
Khan, Farid ;
Brooks, Nati ;
Smaja, Meir ;
Mircus, Gabriel ;
Pan, Kaijie ;
Southern, Jo ;
Swerdlow, David L. ;
Jodar, Luis ;
Levy, Yeheskel ;
Alroy-Preis, Sharon .
LANCET, 2021, 397 (10287) :1819-1829
[7]   COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome (TTS): A Systematic Review and Post Hoc Analysis [J].
Hafeez, Muhammad Usman ;
Ikram, Maha ;
Shafiq, Zunaira ;
Sarfraz, Azza ;
Sarfraz, Zouina ;
Jaiswal, Vikash ;
Sarfraz, Muzna ;
Cherrez-Ojeda, Ivan .
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
[8]   Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study [J].
Homan, Tobias ;
Mazzilli, Sara ;
Chieti, Antonio ;
Musa, Alessandra ;
Roth, Adam ;
Fortunato, Francesca ;
Bisceglia, Lucia ;
Prato, Rosa ;
Lopalco, Pier Luigi ;
Martinelli, Domenico .
SCIENTIFIC REPORTS, 2022, 12 (01)
[9]   Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records [J].
Horne, Elsie M. F. ;
Hulme, William J. ;
Keogh, Ruth H. ;
Palmer, Tom M. ;
Williamson, Elizabeth J. ;
Parker, Edward P. K. ;
Green, Amelia ;
Walker, Venexia ;
Walker, Alex J. ;
Curtis, Helen ;
Fisher, Louis ;
MacKenna, Brian ;
Croker, Richard ;
Hopcroft, Lisa ;
Park, Robin Y. ;
Massey, Jon ;
Morley, Jessica ;
Mehrkar, Amir ;
Bacon, Sebastian ;
Evans, David ;
Inglesby, Peter ;
Morton, Caroline E. ;
Hickman, George ;
Davy, Simon ;
Ward, Tom ;
Dillingham, Iain ;
Goldacre, Ben ;
Hernan, Miguel A. ;
Sterne, Jonathan A. C. .
BMJ-BRITISH MEDICAL JOURNAL, 2022, 378
[10]   Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines [J].
Kahn, Rebecca ;
Schrag, Stephanie J. ;
Verani, Jennifer R. ;
Lipsitch, Marc .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2022, 191 (05) :800-811